A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Summary

A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks

Timeline

Start

2019-09-19

Primary completion

2023-06-13

Completion

2023-06-13

Publications

• Miller A, Cohen JA, Karni A, Popper L, Bleich Kimelman N, Rubnov S, Danon U, Marom E, Boyko A, Zivadinov R, Berger JR, Bar-Or A, Kolb H. GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial. Mult Scler. 2026 Feb;32(2):202-213. doi: 10.1177/13524585251405101. Epub 2026 Feb 18.

Drugs

Indications